In vivo neurometabolic profiling in orthostatic tremor by Benito-León, Julián et al.
Observational Study Medicine®
OPENIn vivo neurometabolic proﬁling in orthostatic
tremor
Julián Benito-León, MD, PhDa,b,c,
∗
, Elan D. Louis, MD, MScd,e,f, Virginia Mato-Abad, PhDg, Ulrike Dydak, PhDh,i,
Juan Álvarez-Linera, MD, PhDj, Juan Antonio Hernández-Tamames, PhDg,
José Antonio Molina-Arjona, MD, PhDa, Norberto Malpica, PhDg, Michele Matarazzo, MDa,
Juan Pablo Romero, MD, PhDa,k, Álvaro Sánchez-Ferro, MDa,l,m
Abstract
The pathogenesis of orthostatic tremor (OT) remains unclear, although some evidence points to dysfunction in the brainstem or
cerebellum. We used single voxel proton magnetic resonance spectroscopy (1H-MRS) (3T) to investigate whether neurochemical
changes underlie abnormal cerebellar or cortical function in OT. Fourteen OT patients and 14 healthy controls underwent 1H-MRS
studies with voxels placed in midparietal gray matter and cerebellum (vermis and central white matter). Spectral analysis
was analyzed using the software package LCModel (version 6.3). The absolute metabolite concentrations and ratios of total
N-acetylaspartate+N-acetylaspartyl glutamate (NAA), choline-containing compounds, myoinositol, and glutamate+glutamine to
creatine were calculated. In midparietal gray matter spectra, we found a signiﬁcant decrease in the absolute concentration of NAA in
OT patients versus healthy controls (7.76±0.25 vs 8.11±0.45, P=0.017). A similar decrease in NAA was seen in the cerebellar
vermis (7.33±0.61 vs 8.55±1.54, P=0.014) and cerebellar white matter (8.54±0.79 vs 9.95±1.57, P=0.010). No differences in
the other metabolites or their ratios were observed. Reductions in both cerebral cortical and cerebellar NAA suggest that there is
neuronal damage or loss in OT, raising the intriguing question as to whether OT is a neurodegenerative disease. Along with clinical
history and electrophysio0logical examination, 1H-MRS could serve as a useful diagnostic aid for OT.
Abbreviations: 1H-MRS= proton magnetic resonance spectroscopy, Cho= choline-containing compounds, Cr= creatine, CSF
= cerebrospinal ﬂuid, ET = Echo Time, EMG = electromyogram, EQ VAS = EQ visual analog scale, EQ-5D = EuroQol-5 dimension,
Glx = glutamate+glutamine, HRQoL = health-related quality of life, IT = Inversion Time, ml =myoinositol, MRI =magnetic resonance
imaging, m-UPDRS = motor portion of the Uniﬁed Parkinson Disease Rating Scale, NAA = N-acetylaspartate+N-acetylaspartyl
glutamate, OT = orthostatic tremor, PRESS = Point Resolved Spectroscopy, RT = Repetition Time, SD = standard deviation.
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Orthostatic tremor (OT), also known as “shaky legs syn-
drome”,[1] is an enigmatic condition that was ﬁrst reported in
1970 by Pazzaglia et al,[2] although Heilman[3] coined the term in
1984. The condition is characterized by tremor in the legs and the
trunk, which begins upon standing. The tremor is accompanied
by a sensation of unsteadiness, which is relieved with walking,
while seated, or while lying down.[4–6] OT may be a family of
diseases, uniﬁed by the presence of regular, rapid lower limb
tremor when standing, and further characterized by etiological
and clinical heterogeneity.[6,7] Gerschlager et al[4] suggested the
subdivision of OT into 2 broad groups—those with “primary
OT” with or without postural arm tremor and those with “OT
plus”, in whom there are additional associated movement
disorders, mainly parkinsonism.
OT is not widely recognized by physicians who are not
movement disorders experts, which often results in misdiagnosis,
who then may be subjected to inappropriate or unnecessary tests
and treatment. In fact, it is often misdiagnosed as essential
tremor, Parkinson disease, restless leg syndrome, lumbar stenosis,
and especially nonorganic (psychogenic) balance disorders.[4,8,9]
Of note, in the differential diagnosis, there are 3 other rare entities
that one should keep in mind. One is orthostatic myoclonus,
disorder that was ﬁrst reported in 2007.[10] This condition is
characterized by unsteadiness during orthostatism and/or during
gait and short-duration myoclonic bursts that occurred predomi-
nately with the assumption of an upright posture.[10] Electro-
myogram (EMG) surface recording is essential for the diagnosis
of this entity.[10] Unlike OT, the bursts are shorter in duration,
nonrhythmic, and irregular.[10] The second one is low-frequency
(4–6Hz) leg tremor in some Parkinson disease, while they are
standing.[11,12] The response of this type of tremor to
dopaminergic drugs is usually good.[11,12] The third one is
“pseudo-orthostatic tremor”, a levodopa-responsive entity,
characterized by 6 to 7Hz with sporadic subharmonics at 8 to
18Hz, clinically manifested by standing tremor, preceding a
parkinsonian syndrome.[13]
The pathogenesis of OT remains unclear, although clinical and
neuroimaging data suggest a possible role of the brainstem or
cerebellum.[5,14–18] Furthermore, cerebellar outﬂow pathways
are the target of high-frequency deep brain stimulators, which are
an effective treatment in someOT patients.[19,20] Of note is that in
a recent case–control comparison, 16 OT patients scored less
than 32 healthy matched controls in numerous cognitive tests,
showing deﬁcits in widespread cognitive domains including
executive function, visuospatial ability, verbal memory, visual
memory, and language.[21] Hence, it is plausible that neuro-
metabolic proﬁling could be altered in the cerebral cortex of OT
patients.
Proton magnetic resonance spectroscopy (1H-MRS), a nonin-
vasive technique, is widely used to assess the neurometabolic
proﬁle of neurological diseases, including tremulous disorders,
such as Parkinson disease, dementia with Lewy bodies and
essential tremor, or dystonia.[22–25] The mainmetabolites detected
by 1H-MRS are N-acetylaspartate+N-acetylaspartyl glutamate
(NAA), creatine (Cr), choline-containing compounds (Cho), and
myoinositol (ml).[26]N-acetylaspartate is mainly found within
neurons, and a reduction in N-acetylaspartate reﬂects neuronal
dysfunction or loss.[26] Cr provides an energy buffer in the brain,
and it includes Cr and phosphocreatine.[26] As an internal
reference, it is stable in different pathophysiological conditions.[26]
Cho is involved in both synthesis and breakdown of phospholipid2membranes. The ml is a marker of glial cells and, therefore, its
concentration is proportional with the extent of gliosis.[26]
To our knowledge, no published 1H-MRS data are available in
OT patients. In order to provide new insights into the
neurochemistry of OT, metabolite levels of NAA, Cr, ml, and
glutamate+glutamine (Glx), as estimated by single voxel 1H-
MRS, were assessed in 14 OT patients and compared to those of
14 age-matched and healthy controls. We hypothesized that there
would be a reduction in NAA in the cerebellum in OT, and,
possibly in the cerebral cortex.
2. Methods
2.1. Participants
Patients with OT were consecutively recruited from December
2011 to May 2013 from the outpatient neurology clinics of the
University Hospital “12 de Octubre” in Madrid (Spain), a public
hospital, which covers an area of more than 400,000 inhabitants.
Four neurologists with expertise in movement disorders (JB-L,
MM, JPR, andAS-F) examined these patientswhowere referred to
the outpatient neurology clinics with a subjective feeling of
unsteadiness when standing, which was absent while walking,
seated, or supine. The neurological examination comprised a
general neurological examination and the motor portion of the
Uniﬁed Parkinson Disease Rating Scale (m-UPDRS).[27] Mild
parkinsonian signs were deﬁned as present when any one of the
following conditions wasmet: 2 ormorem-UPDRS[27] ratings=1,
or 1m-UPDRS[27] rating=2, or them-UPDRS rest tremor rating=
1. Diagnoses of OT were assigned by the 4 neurologists using the
Consensus Statement on Tremor by the Movement Disorder
Society[28]—that is, a suggestive clinical picture of OT (subjective
feeling of unsteadiness during stance without problems when
sitting and lying, and sparse clinicalﬁndings that aremostly limited
to a visible and occasionally, only palpable ﬁne amplitude rippling
of the leg muscles when standing) that is conﬁrmed by EMG
recordings (i.e., synchronized leg tremor present only on standing).
A senior neuropsychologist (Verónica Puertas, see Acknowl-
edgments), specializing in cognitive problems associated with
movement disorders, performed a mental status examination on
each patient and control applying the DSM-IV[29] criteria and
excluded those persons who had dementia. As described
previously,[21] each participant underwent a neuropsychological
assessment, which included a detailed evaluation of cognitive
function, with tests of attention and cognitive processing speed,
executive function, visuospatial ability, verbal memory, visual
memory, language, and mood.
Of 21 eligible OT patients, 7 were excluded from the ﬁnal
cohort. One 92-year-old woman with OT was excluded because
she could not complete the magnetic resonance imaging (MRI)
procedure due to her advanced age, another 81-year-old woman
with OT suddenly died just before the MRI procedure, and 2
women (80 and 92 years) and 3 men (65, 66, and 77 years) with
OT refused to undergo the MRI procedure. No healthy control
was excluded due to incomplete neuropsychological evaluation
or refusal to perform MRI. No participants were excluded
because of major acute comorbidities, neurological comorbid-
ities, dementia, or structural abnormalities on conventional MRI
images.
OT cases were 1:1 frequency-matched with healthy controls.
Frequency-matching was based on age and years of education.
Healthy controls were recruited either from relatives or friends
of the health professionals working at the University Hospital
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patients who came to the neurological clinics for reasons other
than OT (e.g., headache and dizziness). None reported having a
ﬁrst- or second-degree relative with OT or essential tremor. Each
control underwent a standardized neurological examination
performed by 1 of 2 neurologists (JPR and AS-F) to further rule
out any neurological conditions, and by a neuropsychologist, as
noted above.
As there is no validated tool to measure the severity of OT
among patients, we assessed its impact on their health-related
quality of life (HRQoL) by means of the Spanish version of
EuroQol-5 dimension (EQ-5D), a standardized instrument
developed by the EuroQol group, a consortium of investigators
in Europe.[30] The EQ-5D was chosen as the generic HRQoL
measure given its widespread use and its apparent applicability to
other tremor disorders such as Parkinson disease[31] and essential
tremor.[32] EQ-5D consists of 2 parts: the EQ-5D descriptive
system and the EQ visual analog scale (EQ VAS).[30] The EQ-5D
descriptive system comprises 5 dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.[30]
Each dimension has 3 levels (no problems, some problems,
and major problems) and together results in a numeric value that
deﬁnes a health state. EQ-5D scores range between0.594 and 1
(full health).[30] The EQ VAS records the respondent’s self-rated
health on a 20-cm vertical, visual analog scale with endpoints
labeled “the best health you can imagine” (100) and “the worst
health you can imagine” (0).[30]
According to a recently published comorbidity score developed
in ambulatory care settings, a comorbidity index was calculat-
ed.[33] The presence of several conditions (atrial ﬁbrillation,
nonmetastatic cancer, metastatic cancer, chronic obstructive
pulmonary disease, depression, dementia, diabetes, epilepsy
[treated], heart failure, myocardial infarction, psychiatric
disorders, renal disease, and stroke) resulted in the assignment
of more points than others, and the score ranged from 0 to 28
(i.e., all conditions present).[33]2.2. 1H-MRS acquisition
MRI was performed on all OT patients and healthy controls on a
3T system (GE Signa 3T HDxt scanner, General Electric Medical
Systems, Milwaukee, WI) using an 8-channel phased array coil.
TheMRI protocol included a 3-dimensional T1-weighted Spoiled
Gradient Recalled with a Repetition Time=9.24, Echo Time=
4.132ms, Inversion Time=500ms, Number of Excitations=1,
acquisition matrix=256256, full brain coverage, resolution=
0.93750.93751mm3, and ﬂip angle=12. The 1H-MRS
protocol consisted of 3 Point Resolved Spectroscopy (PRESS)
acquisitions with TR=2000ms and TE=35ms. The following
speciﬁc voxels were selected:1. Cerebellar gray matter. The voxel (nominal size=1.51.5
1.8cm3) was placed in the vermis. Aside from a small
proportion of white matter (around 20% of the total volume)
and cerebrospinal ﬂuid (CSF) (around 10%), the voxel
contained mainly gray matter (around 70%). Due to having
to adjust the voxel size minimally in some subjects to match
their head size, the effective voxel size (mean± standard
deviation [SD]) was 4±0.28cm3.
Cerebellar white matter (nominal voxel size: 1.51.51.32.
cm3). Besides a small proportion of graymatter (around 10%),
the voxel contained nearly exclusively white matter (around
90%). The mean voxel size was 3±0.25cm3.33. Midparietal gray matter (nominal voxel size=2.22.22.2
cm3). The mean voxel size was 10±0.19cm3 and mainly
contained gray matter (around 65%), with some white matter
(around 20%) and CSF (around 15%). Our motivation for
including this particular voxel was the recent ﬁnding of
widespread cognitive impairment in OT.[21] In addition, the
same voxel location has been used to quantify metabolites in
other diseases that present with cognitive impairment.[34,35]
Voxel placements and representative spectra from each
location are depicted in Fig. 1. All MRI/1H-MRS acquisitions
and image postprocessing (see below) were performed by a
neuroradiologist (JA-L) and a physicist (VM-A) who were
blinded to the clinical diagnoses.
2.3. 1H-MRS postprocessing
All spectra were analyzed using the sofware package LCModel
(version 6.3) (Stephen Provencher Inc., Oakville, ON,
Canada).[36] The LCModel method automatically performs
phase adjustments, frequency alignment, baseline subtraction,
and eddy current correction. Relative metabolite concentrations
(and their uncertainties) are estimated by ﬁtting the spectrum
to a linear combination of “basis spectra” of each individual
metabolite, obtained from solutions acting as concentration
references for the in vivo acquisitions. For this study, a basis set
provided by the LCModel software for a 3-T PRESS acquisition
with TE=35ms was used. The unsuppressed water spectrum is
then used to normalize the initial ﬁt to generate a ﬁrst estimate
of metabolite concentration in the tissue. LCModel deﬁnes the
concentrations of the pertinent metabolites by scaling the relative
areas and chemical shifts across the 2 sets of spectra. The ﬁtting of
the spectral peaks was thus achieved with a priori knowledge of
their actual characteristics.
The main brain metabolites of interest were the NAA peak at
2.0ppm, the Cr peak at 3.0ppm, the Cho peak at 3.2ppm, the ml
peak at 3.5ppm, and the Glx peak at 2.2 to 2.4ppm.
To deﬁne a criterion for rejection of poor-quality spectra, the
Cramer Rao lower bounds (given as SD%value by the LCModel)
were used. Only those spectra with a SD%<20 were included in
the study. In all these spectra, the linewidth, obtained during the
shimming process, was (on average) 5.75, 6.6, and 6.5Hz for
gray matter of the cerebellum, white matter of the cerebellum,
and midparietal gray matter, respectively, with no signiﬁcant
mean differences between the groups.
Finally, metabolite concentrations obtained from LCModel
were corrected for gray and white matter and CSF content.[37]
The 3-dimensional high-resolution T1-weighted images
were segmented into gray matter, white matter, and CSF using
SPM-8 toolbox (www.ﬁl.ion.ucl.ac.uk/spm/) to determine the
tissue composition of each voxel of interest. Metabolite
quantiﬁcation was adjusted for partial volume effects as
previously described.[37]
All procedures were approved by the ethical standards
committees on human experimentation at the University Hospital
12 de Octubre (Madrid). Written (signed) informed consent was
obtained from all enrollees.
2.4. Statistical analyses
All statistical analyses were performed using SPSS, version 21.0
(IBM Corp., North Castle, NY). Mean scores (age and
neuropsychological variables) were compared using 2 indepen-
dent sample t tests for continuous and normally distributed data,
Figure 1. T1-weighted magnetic resonance image showing the region-of-interest locations used for proton magnetic resonance spectroscopy of midparietal gray
matter (green voxel), cerebellar vermis (blue voxel), and the central cerebellar white matter (red voxel) (A). The spectra shown were obtained from a voxel in the
midparietal gray matter (B), cerebellar vermis (C), and the central cerebellar white matter (D) of a 62-year-old orthostatic tremor patient. The labeled resonances are
those of N-acetylaspartate+N-acetylaspartyl glutamate (NAA), total creatine (Cr), and total choline-containing compounds (Cho). The spectra are plotted on the
same vertical intensity scale normalized to background noise. ppm = parts per million. The absolute concentration of NAA is reduced in this patient compared to the
control group in the 3 voxels, whereas there is minor change in either Cho or Cr.
Benito-León et al. Medicine (2016) 95:37 Medicineand Mann–Whitney U test for nonnormally distributed data,
where appropriate. The x2 test was used to analyze differences in
sex distribution. The peaks of NAA, Cho, ml, and Glx, as well as
NAA/Cr, Cho/Cr, and Glx/Cr, were calculated for each subject
and location and compared using 2 independent sample t tests
because they were all normally distributed. Correlations between
age, years of education, age at onset, disease duration, 17-item
Hamilton Depression Rating Scale total score, comorbidities,
EQ-5D score, cognitive domains, and 1H-MRS metabolites were
determined using Pearson correlation coefﬁcients.3. Results
Clinical details of the OT patients are provided in Table 1. All 14
OT patients were right-handed (mean age 65.0 years, range 37–81
years). There was a female preponderance (N=12, 85.7%) with a
mean age of onset of 55.6 years. All patients presented with
unsteadiness that occurred within seconds of standing and was
relieved by walking or sitting. The symptoms of unsteadiness
coincidedwith theappearanceof tremor in the legs and trunk.Nine
(64.3%) patients presented with primary OT and 5 (35.7%) had4additional neurological features (mild parkinsonian signs). Ten
(71.4%) patients reported a progressive course. Structural brain
MRI was unremarkable in all 14 patients, none had cerebellar
atrophy. Routine blood and chemistry tests including thyroid
function tests, serum protein electrophoresis, and vitamin B12
levels were also in the normal range in all 14 patients. Before MRI
procedure, all 14 OT patients underwent electromyographic
analysis of their leg tremors.This revealed a synchronous10- to18-
Hz leg tremor that was present only on standing. No patients were
being treated with medication for OT (i.e., clonazepam,
dopaminergic drugs, gabapentin, or barbiturates).
The 14 right-handed OT patients (12 women and 2 men)
were compared with 14 right-handed healthy controls (9 women
and 5 men). The OT patients did not differ to a signiﬁcant degree
from the healthy controls in terms of age, sex, years of education,
comorbidity index, and depressive symptoms (Table 2).3.1. 1H-MRS results
All metabolite spectra included in this study had a SD%8% for
NAA, 9% for Cho and Cr, and 14% for ml. The mean NAA
Table 1
Demographic and clinical characteristics of 14 OT patients.
Age, y Sex Age at onset, y Associated neurological features on neurological examination Tremor frequency in lower limbs, Hz
∗
74 Female 67 None 16–18
64 Female 55 None 10–12
57 Male 54 None 16–18
68 Female 62 Mild parkinsonian signs 16–18
78 Female 64 Mild parkinsonian signs 16–18
62 Female 60 Postural upper limb tremor on arm extension 12–16
37 Female 34 None 16–18
76 Female 50 Postural upper limb tremor on arm extension 12–16
75 Female 62 Mild parkinsonian signs 12–16
77 Female 68 Mild parkinsonian signs 12–16
38 Male 17 Postural upper limb tremor on arm extension 16–18
81 Female 74 Mild parkinsonian signs 12–16
65 Female 60 None 16–18
57 Female 51 Postural upper limb tremor on arm extension 16–18
∗
Assessed with electromyography.
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2.13% (SD=0.35) in OT patients and healthy controls,
respectively (Mann–Whitney U test, P=0.715). In the cerebellar
vermis voxel, the mean NAA SD% was 3.54% (SD=0.66) and
3.47% (SD=0.64) in OT patients and healthy controls,
respectively (Mann–Whitney U test, P=0.786). Finally, in the
central cerebellar white matter voxel, the mean NAA SD% was
5.36% (SD=0.63) and 5.07% (SD=1.38) in OT patients and
healthy controls, respectively (Mann–WhitneyU test, P=0.210).
The means and SDs of the metabolite ratios are presented in
Table 3. In midparietal gray matter spectra, we found a
signiﬁcant decrease in the absolute concentration of NAA in
OT patients versus healthy controls (7.76±0.25 vs 8.11±0.45,
P=0.017). A similar difference was also seen in both the
cerebellar gray (vermis) (7.33±0.61 vs 8.55±1.54, P=0.014)
and white matter (8.54±0.79 vs 9.95±1.57, P=0.010). No
signiﬁcant differences in the other metabolites or their ratios were
observed (Table 4).
3.2. Relationships between NAA, demographic and clinical
variables
These correlations were calculated in OT patients only, and only
for the metabolite (NAA), which was different in OT patients
versus control subjects (Table 3). We did not ﬁnd any signiﬁcant
correlation of NAA with demographic and clinical variables
(Table 4).Table 2
Comparison of demographic and clinical variables of OT patients ve
Healthy contr
Age, y 64.8 (66.0
Sex (female) 9 (64.3
Education, y 9.1 (9.5)
Comorbidity index‡ 0.4 (0.0)
17-item Hamilton Depression Rating Scale total score 6.4 (6.5)
Age at onset, y –
Leg tremor duration, y –
Mean (median)± standard deviation and frequency (%) are reported. OT = orthostatic tremor.
∗
Student t test.
† x2 test.
‡ Comorbidity included 13 conditions: atrial ﬁbrillation, nonmetastatic cancer, metastatic cancer, chron
myocardial infarction, psychiatric disorders, renal disease, and stroke.
xMann–Whitney U test.
54. Discussion
We demonstrated a reduction in cerebral cortical and cerebellar
NAA concentration in OT patients, suggesting the presence of
neuronal damage or loss in these regions.
Very little is known about the pathogenesis of OT; however, it
is not typically included among the neurodegenerative disorders.
There is some evidence of a potential role of the nigrostriatal
dopaminergic system in the pathogenesis of OT. For example,
using 123I-FP-CIT single-photon emission computed tomogra-
phy, the dopaminergic system was affected in a group of 11 OT
patients, although to a lesser extent than in Parkinson disease.[38]
When compared to a group of 12 Parkinson disease patients,
tracer uptake in OT patients was signiﬁcantly higher and more
symmetrical, and the caudates and putamens were equally
affected.[38] However, these ﬁndings are not universal, and other
functional imaging studies have showed intact dopaminergic
systems.[39,40]
We demonstrated a reduction in cerebral cortical and
cerebellar cortical viability. While it is possible that the observed
metabolic abnormality in the cerebral cortex and cerebellum is
not a primary pathological event in OT, these data raise the
possibility that OT could be a neurodegenerative disease. Other
clinical data provide some additional support for this possibility.
First, OT is a progressive disorder with increasing disability,
suggesting that the underlying pathological process may not be
static.[41,42] Also, patients who initially present with isolated OTrsus healthy controls.
ols (N=14) OT patients (N=14) P
)±13.2 65.0 (66.9)±13.9 0.959
∗
%) 12 (85.7%) 0.190†
±3.7 8.0 (8.0)±4.9 0.493
∗
±0.8 0.9 (1.0)±1.1 0.178x
±5.3 7.1 (6.0)±6.7 0.782
∗
55.6 (60.0)±14.7
9.5 (7.2)±6.9
ic obstructive pulmonary disease, depression, dementia, diabetes, epilepsy (treated), heart failure,
[43] [44]
Table 3
Absolute concentrations of metabolites andmetabolic ratios in OT
patients versus healthy controls.
Healthy controls (N=14) OT patients (N=14) P
Midparietal gray matter
NAA 8.11±0.45 7.76±0.25 0.017
NAA/Cr 1.31±0.09 1.28±0.07 0.287
Cr 6.19±0.17 6.07±0.30 0.232
Cho 1.15±0.09 1.11±0.10 0.279
Cho/Cr 0.19±0.02 0.18±0.02 0.606
ml 4.60±0.46 4.63±0.44 0.841
ml/Cr 0.74±0.06 0.77±0.08 0.435
Glu+Gln 11.07±0.94 11.02±0.56 0.871
(Glu+Gln)/Cr 1.79±0.17 1.82±0.10 0.640
Cerebellar vermis
NAA 8.55±1.54 7.33±0.61 0.014
NAA/Cr 0.89±0.21 0.80±0.09 0.154
Cr 9.80±1.83 9.19±0.74 0.271
Cho 2.23±0.37 2.08±0.20 0.190
Cho/Cr 0.23±0.04 0.23±0.03 0.741
ml 5.71±1.17 5.31±0.77 0.313
ml/Cr 0.59±0.10 0.58±0.09 0.828
Glu+Gln 13.65±3.57 12.55±1.26 0.297
(Glu+Gln)/Cr 1.40±0.29 1.37±0.10 0.654
Central cerebellar white matter
NAA 9.95±1.57 8.54±0.79 0.010
NAA/Cr 1.82±0.35 1.80±0.30 0.884
Cr 5.59±1.06 4.86±0.86 0.059
Cho 2.00±0.34 1.83±0.24 0.138
Cho/Cr 0.36±0.03 0.38±0.04 0.216
ml 5.73±1.08 5.10±1.22 0.166
ml/Cr 1.04±0.16 1.05±0.21 0.843
Glu+Gln 11.80±2.97 10.50±2.05 0.855
(Glu+Gln)/Cr 2.10±0.24 2.19±0.47 0.499
Mean± standard deviation is reported. Student t tests were used for comparisons. Signiﬁcant values
are in bold font. Cho = choline-containing compounds, Cr = creatine+phosphocreatine, Gln =
glutamine, Glu = glutamate, ml = myoinositol, NAA = N-acetylaspartate+N-acetylaspartyl
glutamate, OT = orthostatic tremor.
Benito-León et al. Medicine (2016) 95:37 Medicineoften later develop additional neurological signs, including
parkinsonism.[42]
Reduction in cerebral cortical and cerebellar NAA concentra-
tion could be explained by neuronal damage or loss, but it could
alternatively be interpreted in terms of changes in energy
demand.[43,44] A gradual reduction in NAA in the visual cortexTable 4
Pearson moment correlations between the absolute NAA
concentration and demographic and clinical variables in 14 OT
patients.
NAA
(midparietal
gray matter)
NAA
(cerebellar
vermis)
NAA
(central cerebellar
white matter)
Age, y 0.211 0.139 0.061
Leg tremor duration, y 0.035 0.015 0.323
Age at onset, y 0.215 0.127 0.074
17-item Hamilton Depression
Rating Scale total score
0.071 0.419 0.019
Comorbidities 0.062 0.299 0.242
EuroQol-5 0.018 0.207 0.230
Euro VAS 0.375 0.029 0.049
None correlation was signiﬁcant. NAA = N-acetylaspartate+N-acetylaspartyl glutamate, VAS = visual
analog scale.
6has been reported, using 3- or 7-T 1H-MRS, during visual
stimulation, with a progressive recovery after the stimulation
ended. Baslow et al[43] proposed that the reduction of NAA
following neuronal activation was related to activation-induced
neuronal release of NAA in the extracellular compartment to
control water distribution. An alternative explanation was put
forward byMangia et al,[44] who proposed that NAA change was
linked to the involvement of this metabolite in the Krebs cycle and
in oxidative metabolism. Thus, the decrease in NAA in OTmight
be linked to a higher energy demand of neurons due to the
increased EMG activity resulting from tremor. In line with this
hypothesis, NAA would be decreased in the areas that represent
the nodes of the network involved in producing the tremor (e.g.,
the cerebellum).
The study should be interpreted within the context of several
limitations. First, the sample size was relatively small. Given the
low incidence and prevalence of the disease, the OT literature
generally comprises studies with small sample sizes. Although
there are no available epidemiological data, in the follow-up
evaluation of the Neurological Disorders of Central Spain
study,[45] we detected only 1 patient with OT in a cohort of
approximately 4000 elderly subjects (data not published).
Despite this limitation, our study was able to detect signiﬁcant
case–control differences. Second, the patients in the present
studymay represent a selected group ofOT patients (i.e., patients
seen in selected outpatient clinics).However, in Spain, health care
is fully state-subsidized, and community-dwelling OT patients
are mainly seen by hospital-based and hospital-associated
neurologists. Third, the recruited sample was quite heteroge-
neous, including primary and OT plus cases. However, our aim
was to examine whether OT patients in general had altered
spectroscopic data when compared with matched healthy
controls.
Despite these limitations, this research represents the ﬁrst
application of 1H-MRS to the study of OT and the ﬁrst to
demonstrate a metabolic abnormality in the brains of OT
patients. This and other future 1H-MRS studies might provide a
novel method to understand the pathophysiological mechanism
of OT. Further, our ﬁndings suggest that 1H-MRS could prove
useful as a useful diagnostic tool in OT, along with the clinical
history and electrophysiological examination.Acknowledgments
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